ROIV Roivant Sciences Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: ROIV

Price (delayed)

$36.82

Market cap

$26.6B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.36

Enterprise value

$25.45B

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 92
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 41
Highlights
The EPS rose by 49% YoY and by 16% QoQ
The net income has increased by 46% year-on-year and by 11% since the previous quarter
ROIV's gross profit has plunged by 73% YoY and by 12% from the previous quarter
Roivant Sciences's revenue has shrunk by 68% YoY and by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://roivant.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of ROIV

ROIV stock price

How has the Roivant Sciences stock price performed over time
Intraday
-3.66%
1 week
-6.95%
1 month
1.43%
1 year
149.8%
YTD
69.68%
QTD
4.04%

Financial performance

How have Roivant Sciences's revenue and profit performed over time
Revenue
$7.53M
Gross profit
$6.12M
Operating income
-$596.14M
Net income
-$266.25M
Gross margin
81.2%
Net margin
-3,535%
ROIV's gross profit has plunged by 73% YoY and by 12% from the previous quarter
Roivant Sciences's revenue has shrunk by 68% YoY and by 9% QoQ
The net margin has dropped by 67% year-on-year but it has increased by 2.6% since the previous quarter
ROIV's operating margin has dropped by 55% year-on-year and by 27% since the previous quarter

Price vs fundamentals

How does ROIV's price correlate with its fundamentals

Growth

What is Roivant Sciences's growth rate over time

Valuation

What is Roivant Sciences stock price valuation
ROIV P/E details
P/E
N/A
P/B
6.26
P/S
3,523.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,379.53
The EPS rose by 49% YoY and by 16% QoQ
The stock's price to book (P/B) is 86% more than its 5-year quarterly average of 3.5 and 59% more than its last 4 quarters average of 4.1
ROIV's equity is down by 7% since the previous quarter and by 2.6% year-on-year
The stock's price to sales (P/S) is 99% more than its last 4 quarters average of 1839.1
Roivant Sciences's revenue has shrunk by 68% YoY and by 9% QoQ

Efficiency

How efficient is Roivant Sciences business performance
The ROIC has soared by 71% YoY and by 14% from the previous quarter
ROIV's return on assets is up by 43% year-on-year and by 12% since the previous quarter
The ROE is up by 40% YoY and by 12% QoQ
The ROS rose by 7% QoQ and by 2.9% YoY

Dividends

What is ROIV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ROIV.

Financial health

How did Roivant Sciences financials performed over time
ROIV's total liabilities has surged by 77% year-on-year but it is down by 8% since the previous quarter
Roivant Sciences's current ratio has shrunk by 59% YoY and by 9% QoQ
The debt is 97% smaller than the equity
The debt to equity has surged by 50% since the previous quarter and by 50% year-on-year
The debt has increased by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.